Passive immunity is protection you receive from antibodies made by someone else, rather than antibodies your own immune system produced. It works immediately, unlike a vaccine, which requires days or weeks to stimulate a response. But borrowed antibodies don’t last. They break down over weeks to months, leaving you without long-term memory of the pathogen. This trade-off between instant protection and short duration shapes every form of passive immunity, from the antibodies a fetus receives in the womb to the engineered monoclonal antibodies administered in a hospital.
How Antibodies Cross the Placenta
The most important natural form of passive immunity begins before birth. IgG, one of the five classes of human antibody, is the only type that crosses the placenta in meaningful quantities. This transfer is not a passive leak. It depends on a specific receptor called the neonatal Fc receptor, or FcRn, which sits on the surface of cells lining the placenta and actively shuttles IgG molecules from the mother’s blood into fetal circulation.1PubMed Central. Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and pre-term newborns Researchers confirmed in the mid-1990s that human FcRn is concentrated in the syncytiotrophoblast, the outer layer of placental tissue that directly contacts maternal blood, placing it exactly where it needs to be to grab and ferry antibodies across.2PubMed. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta
Most of this transfer happens in the third trimester, which means babies born very early may receive far fewer maternal antibodies than full-term infants. By birth, a healthy full-term newborn can actually have IgG concentrations equal to or slightly higher than the mother’s, because FcRn actively concentrates antibodies rather than just allowing them through. The protection this confers covers whatever infections the mother’s immune system has encountered or been vaccinated against, including measles, tetanus, and pertussis. It is a head start, not a permanent shield.
Breast Milk and the Mucosal Layer
After birth, the natural pathway continues through breastfeeding, but the mechanism is different. Breast milk is rich in IgA rather than IgG. These antibodies are not absorbed into the infant’s bloodstream in significant amounts. Instead, they coat the lining of the baby’s respiratory and digestive tracts, creating a protective layer right where pathogens are most likely to enter.3PubMed Central. Antibodies in breast milk: Pro-bodies designed for healthy newborn development This mucosal defense is particularly valuable in the first weeks of life, when the infant’s own immune system is still immature and not yet producing adequate IgA of its own.
Breast milk antibodies reflect the mother’s own immune history, which means they are tailored to the pathogens circulating in the same environment the baby inhabits. A mother exposed to a local strain of rotavirus, for example, will produce IgA against that strain, and the baby gets front-line defense without ever mounting its own immune response. The protection fades once breastfeeding ends, and it does not generate immune memory in the child. But its impact on reducing infections in infancy has been documented across populations in both high- and low-income countries.3PubMed Central. Antibodies in breast milk: Pro-bodies designed for healthy newborn development
How Quickly Passive Immunity Fades
One of the defining features of passive immunity is that borrowed antibodies degrade on a predictable schedule. A meta-analysis pooling data from individual infants found that the half-lives of maternal antibodies against diphtheria, tetanus, and pertussis antigens were remarkably similar, ranging from roughly 29 days for tetanus toxoid antibodies to about 35 days for pertactin antibodies.4PubMed Central. The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis That means antibody levels roughly halve every month. Within three to six months, concentrations drop below the level needed to protect against these diseases, which is one of the main reasons pediatric vaccine schedules begin at two months of age.
Interestingly, the rate of decay did not differ meaningfully based on the mother’s age, whether she had been vaccinated, or the baby’s birthweight or gestational age at delivery.4PubMed Central. The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis What did matter was the starting concentration: babies born with higher antibody levels stayed protected longer simply because it took more half-lives to drop below the threshold. This is why maternal vaccination during pregnancy, which boosts the mother’s antibody levels right before the period of maximal placental transfer, extends the window of infant protection.
Why Maternal Antibodies Complicate Infant Vaccination
Here is an underappreciated wrinkle. The same maternal antibodies that protect a newborn can also interfere with the infant’s response to vaccines. When a baby is vaccinated, the injected antigen is supposed to trigger the infant’s own B cells to produce antibodies and form immune memory. But if maternal antibodies are still circulating at high enough levels, they can bind to the vaccine antigen and neutralize it before the infant’s immune system gets a chance to respond fully.5PubMed. Effect of maternal antibodies on the infant immune response
This blunting effect is one reason why some vaccines require multiple doses in the first year. The first dose given at two months may face significant interference from residual maternal antibodies, producing only a partial response. The second and third doses, given after more maternal antibody has decayed, tend to generate progressively stronger responses. Measles vaccine is a classic example: in countries where maternal measles antibody levels are high, the first dose is sometimes delayed until nine months or even twelve months to avoid interference. The timing is a balancing act between the risk of the child catching measles before vaccination and the risk of the vaccine not working well if given too early.
Antitoxins and Immune Globulins
On the artificial side, the oldest form of passive immunity involves injecting antibodies harvested from the blood of humans or animals who have already mounted an immune response. Diphtheria antitoxin, developed over a century ago, was one of the first medical applications of this principle. It consists of antibodies purified from the serum of horses immunized against the diphtheria toxin, and it remains the standard treatment for active diphtheria infection, though supply is limited and it is not commercially available in the United States.6PubMed Central. Identification of a human monoclonal antibody to replace equine diphtheria antitoxin for treatment of diphtheria intoxication
The obvious problem with animal-derived antibodies is that the human immune system recognizes them as foreign proteins, which can trigger allergic reactions or serum sickness. This drove the development of human immune globulin products, purified from pooled human donor plasma. Standard intravenous immunoglobulin (IVIG) contains a broad mix of IgG antibodies reflecting the collective immune experience of thousands of donors. It is used to treat immunodeficiency disorders, certain autoimmune conditions, and acute infections.
Hyperimmune globulins take this a step further. They are prepared from donors with particularly high antibody levels against a specific pathogen, whether from natural infection or deliberate immunization. Rabies immune globulin is a familiar example: it is injected at the site of an animal bite alongside the rabies vaccine to provide immediate neutralizing antibodies while the vaccine takes days to stimulate the person’s own response. In clinical studies, subjects who received rabies immune globulin plus vaccine maintained protective antibody levels from two weeks through at least six weeks, while those who received the immune globulin alone saw their antibody levels fall below the protective threshold by the sixth week.7Biologicals. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies That pattern captures the core logic of combining passive and active immunity: the borrowed antibodies buy time for the vaccine to kick in.
Rh immunoprophylaxis is another targeted use of passive antibody injection, though the goal is different. When an Rh-negative mother carries an Rh-positive fetus, fetal red blood cells can enter her circulation and trigger an immune response against the Rh D antigen. Injecting anti-D immunoglobulin during and after pregnancy prevents this sensitization, protecting future pregnancies from hemolytic disease of the newborn.8Journal of Obstetrics and Gynaecology Canada. Prevention of Rh D Alloimmunization Here, passive immunity is not protecting against a pathogen but intercepting the mother’s immune system before it can mount a harmful response.
Monoclonal Antibodies and Convalescent Plasma
Modern biotechnology has made it possible to produce highly specific antibodies in a laboratory rather than harvesting them from blood. Monoclonal antibodies are engineered copies of a single antibody, mass-produced by identical cell lines. They can be designed to target one precise site on a virus or toxin with far greater consistency than pooled human immunoglobulin. During the COVID-19 pandemic, several monoclonal antibodies received emergency use authorization for treating mild to moderate illness. Monoclonal antibodies against respiratory syncytial virus, or RSV, have also entered clinical use, particularly for protecting infants and immunocompromised adults.9PubMed. Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections
Convalescent plasma occupies a middle ground between the old and the new. It involves collecting plasma from people who have recovered from an infection and transfusing it to patients currently ill with the same disease. The idea is straightforward: recovered individuals carry neutralizing antibodies, and those antibodies can help a sick person fight the pathogen. During the COVID-19 pandemic, this approach was deployed at massive scale. Evidence from matched-control studies generally showed improved survival, and randomized trials found a survival benefit when convalescent plasma was transfused early in the disease course, though later transfusion, once patients already needed intensive support, showed limited or no benefit.10PubMed Central. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence Timing, as with so much in passive immunity, turned out to be critical.
When Borrowed Antibodies Backfire
Passive immunity is not always benign. One of the most concerning paradoxes in immunology is antibody-dependent enhancement, or ADE, where antibodies that are present at levels too low to neutralize a virus actually help the virus infect more cells. Dengue is the best-studied example. When someone has antibodies against one dengue serotype at subneutralizing concentrations, those antibodies can latch onto a different serotype without disabling it, then carry the virus into immune cells via Fc receptors on the cell surface, effectively giving the virus a backdoor into cells it might not otherwise infect efficiently.11The Journal of Immunology. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection
This phenomenon is not limited to dengue or even to human viruses. Researchers have demonstrated Fc receptor-mediated antibody-dependent enhancement in systems as unexpected as bacteriophage gene transfer in mammalian cells, showing that the basic mechanism is widely conserved wherever Fc receptors and antibody-opsonized particles meet.12PubMed Central. Fc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells ADE was a significant concern during COVID-19 monoclonal antibody development and is a recurring worry in dengue vaccine design. It illustrates why simply having antibodies present is not always the same as being protected: the quantity, specificity, and binding strength all matter.
Beyond ADE, animal-derived antibody products carry the risk of serum sickness, an immune-complex reaction that causes fever, joint pain, rash, and sometimes kidney inflammation. Even human-derived products can cause infusion reactions, headaches, and, in rare cases, anaphylaxis. The risks are generally manageable, but they explain why passive immunization is usually reserved for situations where the benefit of immediate protection clearly outweighs these downsides, such as post-exposure prophylaxis for rabies or tetanus, or treatment of severe immunodeficiency.
How Other Animals Handle Passive Immunity
Humans transfer the bulk of maternal antibodies across the placenta before birth and top up mucosal protection through breast milk afterward. But this split is far from universal among mammals. The degree to which antibodies cross the placenta depends on placental structure, which varies dramatically across species. In animals with hemochorial placentas, where maternal blood directly bathes fetal tissue, like humans, rabbits, and rodents, substantial antibody transfer happens before birth. But in species with epitheliochorial or synepitheliochorial placentas, such as horses, cattle, sheep, and pigs, the barrier between maternal and fetal circulation is too thick for antibodies to pass through.13PubMed. A review of immune transfer by the placenta
For these animals, colostrum, the first milk produced after birth, is the sole source of passive immunity. Newborn calves, foals, and piglets are born with essentially no circulating antibodies and depend entirely on absorbing immunoglobulins from colostrum through their gut within the first hours of life. Because of this total reliance on postpartum transfer, colostrum in ungulates has far higher IgG concentrations than human colostrum, which instead contains more IgA for mucosal protection since the baby has already received IgG in the womb.14PubMed Central. Implications of placentation type on species-specific colostrum properties in mammals A calf that fails to nurse within the first 24 hours faces a dramatically higher risk of fatal infection, a well-known problem in livestock management called failure of passive transfer.
Birds solve the problem differently still. Because there is no placenta, hens deposit IgY, the avian equivalent of IgG, directly into the egg yolk during formation. The developing chick absorbs these antibodies from the yolk sac before hatching.15The Journal of Poultry Science. Maternal Transfer of Immunoglobulins into Egg Yolks of Birds Research in meat-type chickens found that IgY levels in the hen’s plasma or eggs were a direct indicator of how much maternal antibody ended up in the chick’s circulation, with roughly 30% of the hen’s specific antibody transferring to the offspring.16PubMed. Maternal antibody transfer from dams to their egg yolks, egg whites, and chicks in meat lines of chickens Poultry vaccination programs exploit this: vaccinating breeder hens against common diseases transfers protective antibodies to their chicks through the eggs.
Even invertebrates have a version of maternal immune transfer, though it looks nothing like antibody-mediated protection. In insects, a process called transgenerational immune priming allows mothers to pass pathogen-specific information to their offspring. The mechanism involves transferring fragments of microbes the mother encountered, often bound to yolk proteins, into the developing eggs. This primes the offspring’s innate immune defenses against threats they are likely to face in the same environment.17PubMed. Mechanisms of transgenerational immune priming in insects It is not passive immunity in the classical antibody-transfer sense, but it serves the same evolutionary purpose: giving newborns a defensive head start using the mother’s immune experience.
Oral Passive Immunotherapy
One approach that blurs the line between natural and artificial passive immunity is the oral delivery of specific antibodies to protect the gut. Rather than injecting antibodies into the bloodstream, you can deliver them to the gastrointestinal tract directly, similar to how breast milk IgA works. Bovine antibodies from cows immunized against human pathogens have been tested in this role. In challenge studies, a daily oral dose of just five grams of bovine immunoglobulin from hyperimmunized cows provided complete protection against E. coli infection in adult volunteers.18PubMed Central. Passive immunity against human pathogens using bovine antibodies The antibodies do not need to survive digestion intact throughout the entire gut; they work by neutralizing pathogens in the upper digestive tract, much like the mucosal defense breast milk provides for infants.
This approach has potential appeal for travelers, immunocompromised patients, and settings where clean water is unreliable. It sidesteps many of the problems of intravenous antibody therapy: no injection-site reactions, no need for clinical infrastructure, and lower risk of systemic side effects. The downside is that oral antibodies protect only the gut, not the bloodstream or lungs, so their applications remain narrow.
Engineering Longer-Lasting Passive Protection
The biggest limitation of passive immunity has always been its short duration. Standard IgG antibodies circulate for a few weeks before the body clears them. Researchers are now trying to extend that window through molecular engineering. One strategy modifies the Fc region of a monoclonal antibody, the tail portion that interacts with FcRn, the same receptor responsible for transporting maternal IgG across the placenta. In circulation, FcRn also acts as a recycling receptor: it binds IgG inside cells, prevents it from being broken down, and releases it back into the bloodstream. By tweaking the antibody’s Fc region to bind FcRn more tightly, researchers can increase how efficiently antibodies are recycled, extending their effective half-life. A novel antibody drug candidate targeting inflammatory bowel disease, for instance, incorporates a specific modification in its Fc region to boost FcRn affinity and favor recycling over degradation.19Journal of Crohn’s and Colitis. P587 Development and Characterization of a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting Integrin É‘4β7 for the Treatment of IBD
An even more radical approach skips the antibody manufacturing process altogether. Instead of producing monoclonal antibodies in bioreactors and injecting the finished proteins, researchers are developing mRNA-based delivery systems that encode the antibody’s genetic instructions inside lipid nanoparticles. Once injected, the mRNA enters cells, where it is translated into functional antibodies by the cell’s own protein-making machinery.20PubMed Central. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy This is still passive immunity, because the resulting antibodies are predefined by the mRNA sequence rather than generated by the recipient’s adaptive immune system. But it could dramatically reduce production costs, since growing and purifying proteins in bioreactors is expensive and slow. It could also extend the duration of protection, because the body continues producing the antibody for as long as the mRNA persists, rather than receiving a single bolus that starts decaying immediately.21PubMed Central. Advancements in mRNA Encoded Antibodies for Passive Immunotherapy
This technology is still in development, and questions remain about how well the approach scales, how the immune system responds to repeated mRNA dosing, and whether in-vivo-produced antibodies fold and function as reliably as those made in controlled bioreactor conditions. But it represents a genuine shift in thinking about passive immunity: instead of borrowing someone else’s antibodies, you borrow their antibody blueprint and let your own cells do the manufacturing.